Navigation Links
Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
Date:12/3/2013

e">Michael A. Martino, President and CEO of Ambit. "We believe that our data demonstrates the clinical value and benefit of quizartinib for patients in an area of clear and high unmet medical need.  We look forward to presenting our data at ASH next week and anticipate a high level of clinical enthusiasm."

Data from quizartinib studies will be presented at the ASH 55th Annual Meeting at the Ernest Morial Convention Center in New Orleans, LA on December 9, 2013. 

Oral Presentations:

Results of Phase 2 Randomized, Open-Label, Study of Lower Doses of Quizartinib in Subjects with FLT3-ITD Positive Relapsed Acute Myeloid Leukemia (AML): The purpose of this study is to assess the efficacy and safety of lower doses of quizartinib in the treatment of patients 18-years or older with relapsed/refractory FLT3 ITD positive AML to further improve the benefit:risk assessment of quizartinib. The data will be presented by Dr. Jorge Cortes at 3:00 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

Quizartinib Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Experience From The AML Pilot Trial: This is the first presentation of quizartinib use in combination with chemotherapy in newly diagnosed older AML patients, testing the feasibility and dose which could be given sequentially following conventional chemotherapy in patients over the age of 60 years. The data will be presented by Dr. Alan Burnett at 5:15 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

Results of Phase 1 Study of Quizartinib In Combination with Induction and Consolidation Chemotherapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: This dose escalation study is the first to report data on quizartinib in combination with standard indu
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
2. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
3. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
4. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
5. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
6. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
7. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
10. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
11. Neodyne Biosciences Announces Issuance of U.S. Patent for Devices and Methods for Dressing Applicators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... ALBANY, New York , July 11, 2014 /PRNewswire/ ... published by Transparency Market Research "Endoscopy Devices Market (Endoscopes, ... Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019" the ... billion in 2012 and is expected to grow at ... reach an estimated value of USD 36.9 billion in ...
(Date:7/11/2014)... , July 11, 2014 ... to Safety & Health Expo 2014 were ... move to London , ... attending exhibition.          ... http://photos.prnewswire.com/prnh/20140711/696892-a )      (Photo: ...
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... BellaNovus Development Company LLC, a medical design ... the Ouchless™ Needle Collection. The devices provide doctors ... creams and ice currently used to minimize localized ... and dermal fillers. Offered in three models, Ouchless™ ...
... CIVCO Medical Solutions is showcasing its RFSuite RFID tracking ... also hosting an RFSuite Symposium Monday, August 1st, from ... the Fairmont Waterfront, Vancouver. The event will include lunch, ... Click here to view the invitation and register . ...
Cached Medicine Technology:New Ouchless™ Needle Collection Revolutionizes Wrinkle Treatments With State-of-the-Art Pain Reducing Technology 2CIVCO Showcases RFSuite RFID Tracking and Verification System at AAPM 2011 Booth #817 2CIVCO Showcases RFSuite RFID Tracking and Verification System at AAPM 2011 Booth #817 3
(Date:7/14/2014)... York, NY (PRWEB) July 14, 2014 ... app on iTunes, called Love Digits. The App brings ... and couples alike to quantify their compatibility using a ... and places, two people can instantaneously test their compatibility ... Chinese astrology measures. , The app’s five-star rating system ...
(Date:7/14/2014)... New research and analysis from the ... Earth examines toxic ingredients in tampons, a product ... specific chemicals that may be found in the product’s ... may put women’s health at risk. , According ... Scranton , the potential impact of toxic chemical exposure ...
(Date:7/13/2014)... Recently, MagicQuinceaneraDresses.com, a well-known special occasion dress manufacturer and ... Dama dresses . Furthermore, the company’s sales manager has ... sale. They are available at greatly discounted prices, up ... to unveil the cheap, fashionable Dama gowns. “By launching ... for our fans. It will last until July 26. ...
(Date:7/13/2014)... Denver, CO (PRWEB) July 13, 2014 ... in conjunction with the 2014 Guinness International Champions Cup. ... on American soil each year because of the talent of ... Manchester United and AS Roma will compete in the 2014 ... off on July 24 with a game between Olympiacos and ...
(Date:7/13/2014)... Failure to get the best treatment and variations in ... why survival for blood cancer patients still varies widely ... study of survival in European adults to date, published ... news is that 5-year survival for most cancers of ... most likely reflecting the approval of new targeted drugs ...
Breaking Medicine News(10 mins):Health News:Love Digits, Numerical Approach to Modern Love, Now Available on iTunes 2Health News:Love Digits, Numerical Approach to Modern Love, Now Available on iTunes 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 2Health News:New Patent Analysis Shows Toxic Risk From Tampons 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 4Health News:New Patent Analysis Shows Toxic Risk From Tampons 5Health News:Fashionable Dama Dresses Unveiled By Well-known Supplier MagicQuinceaneraDresses.com 2Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 2Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 3Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3
... , SATURDAY, June 4 (HealthDay News) -- Breast cancer ... diagnosis have a lower chance of surviving, a new study ... cancer and obesity only in estrogen receptor-positive forms of the ... breast cancer. "This relationship between dying and being obese ...
... a healthy body weight before and after diagnosis of breast ... a new study finds. The results will be presented Saturday ... The study, conducted in nearly 4,000 breast cancer survivors, found ... cancer. In particular, overweight or obese women with a history ...
... radiation treatment improves disease free survival lessening the chance ... who have had breast conserving surgery (lumpectomy), interim results ... presented Monday, June 6 at the annual meeting of ... results are potentially practice-changing," said Dr. Timothy J. Whelan, ...
... Reporter , FRIDAY, June 3 (HealthDay News) -- Early ... the cancer,s return drop by 32 percent when the ... for three years after surgery, Austrian researchers report. ... to develop osteoporosis, so they are usually given a ...
... June 3 (HealthDay News) -- Providing children with more toys ... researchers say. The new study also found that having ... play among children, particularly girls. In the ... of Buffalo in New York, researchers offered three different quantities ...
... M.D., Ph.D. , the associate director of the Acute and ... a Career Development Award from the Conquer Cancer Foundation of the ... Foundation) at the annual ASCO meeting this weekend in ... at the Mayo Clinic News Blog . Dr. ...
Cached Medicine News:Health News:Excess Pounds May Lower Odds of Surviving Breast Cancer 2Health News:Obesity raises breast cancer survivors' risk of dying of the cancer 2Health News:Breast cancer surgery patients benefit from adding radiation therapy 2Health News:Bone Drug Reduces Odds for Breast Cancer's Return: Study 2Health News:Bone Drug Reduces Odds for Breast Cancer's Return: Study 3Health News:Having More Toys May Boost Exercise Levels in Kids 2Health News:Mayo Clinic: Raoul Tibes, M.D., Ph.D., to receive Career Development Award 2
... Easy Breeze Air Gel Dryer : Dry up ... 24 gels 8 10 cm without a ... rapid drying, or no heat for controlled drying ... transparent, dried gels. Add and remove gels at ...
Each GelAir™ system drying frame includes two main components, a plastic drying outer frame and a metal square inner frame, as well as 8 clamps per frame. Supplied as a set of two frames....
... Breeze Air Gel Dryer : Dry up to ... gels 8 10 cm without a vacuum ... drying, or no heat for controlled drying of ... dried gels. Add and remove gels at any ...
... SGD5040 Slab Gel Dryer incorporates sturdy metal housing and ... The large surface area makes it perfect for drying ... Slim Profile 40cm x 50cm (W x D) ... Rates allows you to optimize your heating ...
Medicine Products: